Bernhard Ehmer is chairman of the Board of management of Biotest AG since January 2015. Prior to this he worked for the Imclone Group, a wholly owned subsidiary of Eli Lilly as president of Imclone Systems Corporation in the US and as managing director in Germany. 2007/2008 he was CEO of Fresenius Biotech, Germany. From 2000 until 2005 Bernhard Ehmer headed the Business Area Oncology of Merck KgaA, Darmstadt - from 1998 until 2000 he was head of "Global Clinical Operations" at Merck. Between 1986 and 1998 he held various functions at Boehringer Mannheim in Germany, Italy and Singapore.